Mersana Therapeutics. has filed a patent for fully human monoclonal antibodies that recognize HER2. The patent also includes methods for using these antibodies in therapeutic, diagnostic, and prophylactic applications. The invention aims to identify antibodies or antigen binding fragments that bind to the HER2 receptor at a specific epitope. GlobalData’s report on Mersana Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Mersana Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mersana Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Mersana Therapeutics's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

Fully human monoclonal antibodies that recognize her2 receptor

Source: United States Patent and Trademark Office (USPTO). Credit: Mersana Therapeutics Inc

A recently filed patent (Publication Number: US20230265197A1) describes a method for identifying an antibody or antigen binding fragment that binds to a specific epitope on the human HER2 receptor. The method involves contacting an immobilized HER2 receptor polypeptide with a first antibody or antigen binding fragment and a second antibody or antigen binding fragment. The researchers then determine whether the second antibody competes for binding to the HER2 receptor with the first antibody. If the second antibody competes for binding, it indicates that it binds to the HER2 receptor at the defined epitope.

The patent also mentions that either the first or second antibody or antigen binding fragment can be labeled, with detectable fluorescent or radioactive markers being examples of labels. The immobilized HER2 receptor polypeptide can be expressed on a cell surface or on a solid support, such as a biosensor. The JIMT-1 cell line is specifically mentioned as an example of a cell that can express the HER2 receptor polypeptide.

The first antibody or antigen binding fragment described in the patent comprises specific amino acid sequences for the variable heavy chain complementarity determining regions (CDRH1, CDRH2, and CDRH3) and the variable light chain complementarity determining regions (CDRL1, CDRL2, and CDRL3). The patent also mentions that the second antibody or antigen binding fragment can be obtained by screening a library of antibody or antigen binding domain sequences expressed in display type technologies, such as phage display, retroviral display, or ribosomal display.

The patent further describes various types of antibodies or antigen binding fragments that can be used in the method, including monoclonal antibodies, domain antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, single chain variable fragments (scFv), scFv-Fc fragments, single chain antibodies (scAb), domain antibodies (dAb), single domain heavy chain antibodies, and single domain light chain antibodies. These antibodies or antigen binding fragments can be of different isotypes, such as rabbit, mouse, chimeric, humanized, or fully human monoclonal antibodies, with the IgG1 isotype specifically mentioned.

In summary, the patent describes a method for identifying antibodies or antigen binding fragments that bind to a specific epitope on the human HER2 receptor. The method involves contacting an immobilized HER2 receptor polypeptide with two antibodies or antigen binding fragments and determining whether they compete for binding. The patent also provides details on the specific amino acid sequences, labeling options, cell lines, solid supports, and types of antibodies or antigen binding fragments that can be used in the method.

To know more about GlobalData’s detailed insights on Mersana Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies